9 Oct

Analysts’ Estimates and Ratings for Novartis in October

WRITTEN BY Mike Benson FEATURED IN Company News, Insights, & Analysis

Analysts’ revenue estimates

Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

Analysts expect the company’s EPS to be $1.31 on revenue of $13.0 billion in the third quarter, a ~5.0% rise compared to $12.4 billion in the third quarter of 2017.

Analysts’ Estimates and Ratings for Novartis in October

The above chart compares the changes in analysts’ recommendations for Novartis since January.

Analysts’ recommendations

Analysts expect Novartis to return ~15.5% over the next 12 months. Analysts’ recommendations show a 12-month target price of $98.50 compared to its price of $85.26 on October 8.

Two analysts are tracking Novartis’s ADR (American depositary receipt). Both analysts have given it “strong buy” recommendations. No analysts have given it “holds” or “sells.”

Also, 26 analysts are tracking Novartis stock on the SIX Swiss Exchange. Of these, seven analysts have recommended “strong buys,” eight have recommended “buys,” and 11 have recommended “holds” on the stock. No analysts have recommended “sells.” The consensus rating for Novartis stock stands at 2.15, which represents a “strong buy” for long-term investors.

The Invesco BLDRS Developed Markets ADR ETF (ADRD) holds 5.4% of its total investments in Novartis, 2.5% in Sanofi (SNY), 2.5% in GlaxoSmithKline (GSK), and 2.5% in AstraZeneca (AZN).

Latest articles

Monster Beverage (MNST) stock was down 1.6% as of 2:47 PM EDT on March 20.

Earlier today, the second-largest US automaker by 2018 sales volume, Ford Motor Company (F), revealed its plan to invest $850 million in its Flat Rock assembly plant through 2023.

Mizuho downgraded Yum! Brands (YUM) from “neutral” to “underperform” while keeping its 12-month price unchanged at $84, which represents a fall of 15.4% from its March 19 closing price of $99.20.

20 Mar

Why Verizon Sought to Lead 5G Rollout

WRITTEN BY Rachel Gunter

According to Verizon, its mobile 5G plans will cost $10 more than its current 4G plans.

As of March 19, Dunkin’ Brands (DNKN) was trading at $71.55, which represents a rise of 3.9% since the announcement of its fourth-quarter earnings on February 7.

Suncor Energy's shareholder returns have grown consistently over the past few years. The company hasn't forgotten its commitment to growth.